What is the history of Prader-Willi Syndrome?

Prader-Willi Syndrome was first formally characterized in 1956 by Swiss physicians Andrea Prader, Alexis Labhart, and Heinrich Willi, who identified a common cluster of symptoms including obesity, short stature, and intellectual disability. Since its discovery, medical understanding of Prader-Willi Syndrome has evolved from a purely clinical observation to a complex genetic diagnosis involving the loss of function of specific genes on chromosome 15.

Who first discovered Prader-Willi Syndrome?

While reports of individuals with similar symptoms appeared in medical literature as early as the 19th century, the condition was not formally defined until the 1956 paper by pediatricians Andrea Prader and Heinrich Willi, and endocrinologist Alexis Labhart. They observed a group of children who shared a distinct phenotype, including infantile hypotonia (low muscle tone), hyperphagia (insatiable hunger), and developmental delays. This seminal work brought Prader-Willi Syndrome into the clinical spotlight, distinguishing it from other causes of childhood obesity and failure to thrive.

How has our understanding of Prader-Willi Syndrome evolved?

For decades, Prader-Willi Syndrome was managed primarily through symptom control, as the underlying cause remained unknown. A massive paradigm shift occurred in the early 1980s when researchers identified a deletion on the paternal copy of chromosome 15 (q11-q13). This discovery was a milestone in medical genetics, as it was one of the first human conditions linked to genomic imprinting—a process where genes are expressed differently depending on whether they are inherited from the mother or the father. Today, we know that Prader-Willi Syndrome occurs due to the lack of expression of paternal genes in this region, whether through deletion, maternal uniparental disomy, or an imprinting defect.

What were the major milestones in treatment and diagnosis?

The history of Prader-Willi Syndrome management has moved from observation to proactive intervention. Key historical milestones include:

• 1956: First clinical description by Prader, Labhart, and Willi.


• 1981: Identification of the chromosome 15q11-q13 deletion.


• 2000: FDA approval of growth hormone (GH) therapy for Prader-Willi Syndrome, which significantly improved height, body composition, and muscle mass in children.


• Modern Era: Development of specialized multidisciplinary clinics and focus on early intervention for neurodevelopmental support.

How did advocacy change the landscape for patients?

Historically, misconceptions—such as the idea that the hyperphagia associated with Prader-Willi Syndrome was a behavioral choice rather than a physiological dysfunction of the hypothalamus—led to significant stigma. Over time, the rise of patient advocacy groups, such as the Prader-Willi Syndrome Association (PWSA), shifted the narrative. These organizations have been instrumental in educating the medical community, promoting research, and building a supportive environment for the 241 members currently connected through DiseaseMaps.org. Advocacy has successfully reframed the condition from a "behavioral problem" to a complex neuroendocrine disorder requiring lifelong support.

Next steps

• Consult with a clinical geneticist to review specific genetic testing results.


• Connect with the community at DiseaseMaps.org to share experiences with other families.


• Follow updates from the Prader-Willi Syndrome Association regarding current clinical trials and research.


• Schedule regular check-ups with an endocrinologist experienced in managing hormone deficiencies.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Prader-Willi Syndrome.


• Orphanet: Prader-Willi Syndrome (ORPHA:739).


• Online Mendelian Inheritance in Man (OMIM): #176270.


• Prader-Willi Syndrome Association (PWSA-USA) historical archives.